Company: TAK
Filing Date: 2025-09-08
Form Type: 6-K
Source: 0001395064-25-000130
Chunk: 1

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-09-08
Form: 6-K
Chunk 1
---
<div align='center'>Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025</div>

SINGAPORE, OSAKA, Japan and CAMBRIDGE, Massachusetts, September 8, 2025 – Takeda (TSE:4502/NYSE:TAK) will present data from two global Phase 3 double-blind, placebo-controlled studies of oveporexton (TAK-861), a potential first-in-class investigational oral orexin receptor 2 (OX2R)-selective agonist in narcolepsy type 1 (NT1), during multiple oral presentations at the World Sleep 2025 Congress in Singapore beginning at 3:15 p.m. SGT today. Please refer to the attached press release and presentation for details.

The topline results of these studies were disclosed on July 14, 2025 in, “Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1”.

| Media Contact:             |     | Investor Contact:              |
| Rachel Wallace             
 rachel.wallace2@takeda.com |     | Christopher O’Reilly           
 christopher.oreilly@takeda.com |

Results from these studies have no significant impact on the full year consolidated forecast for the fiscal year ending March 31, 2026.

<div align='center'>###

Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025

– Takeda is the Leader in Orexin Science and is on Track to Submit Global Regulatory Applications Starting in Fiscal Year 2025

– Four Orexin Oral Presentations from Phase 3 Pivotal Studies Highlight Statistically Significant and Clinically Meaningful Improvement in Narcolepsy Type 1 Symptoms Demonstrating the Potential for a New Era of Care

– Oveporexton was Generally Well-Tolerated with Safety Profile Consistent with Previous Clinical Studies</div>

SINGAPORE, OSAKA, Japan and CAMBRIDGE, Massachusetts, September 8, 2025 – Takeda (TSE:4502/NYSE:TAK) will present data from two global Phase 3 double-blind